Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynamin-1-like protein (DNM1L), commonly known as dynamin-related protein 1 (DRP1), is a large GTPase belonging to the dynamin superfamily that plays a central role in regulating mitochondrial and peroxisomal fission. Under physiological conditions, DRP1 is recruited from the cytosol to the outer mitochondrial membrane by adaptor proteins (such as Mff, Fis1, and MiD49/MiD51) where it oligomerizes to form ring-like structures that constrict and sever the membrane in a GTP-dependent manner. This process is critical for maintaining mitochondrial network morphology, quality control via mitophagy, and cellular homeostasis. Dysregulation of DRP1, particularly excessive activation leading to pathological mitochondrial fragmentation, is implicated in the pathogenesis of neurodegenerative diseases (such as Alzheimer's and Parkinson's), cardiovascular diseases (including ischemia-reperfusion injury), and metabolic disorders. Conversely, loss-of-function mutations in the DNM1L gene cause rare, severe neurodevelopmental disorders. Consequently, DRP1 has emerged as a promising therapeutic target, with several small-molecule and peptide inhibitors (such as Mdivi-1, DRP1i27, and P110) being investigated in preclinical models to restore mitochondrial dynamics and protect against cell death.
Inhibition of GTPase activity or disruption of recruitment to the mitochondrial outer membrane to prevent mitochondrial fission
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynamin-1-like protein (DRP1).